Through the integration of Hoechst Marion Roussel and Rhone-Poulenc Rorer, Aventis is creating a truly global, inexorably interlocked network of drug discovery and development capabilities. The need to improve sales performance and increase capitalization--a defense against takeover--drove the merger. But the merger also gave it both more R&D resources and an opportunity to retool its process. As this question and answer session with Aventis's Frank Douglas, head of R&D, notes, the company is emphasizing the creation of capabilities through internal and external investments, rather than scale. The reconfiguration draws on Douglas's experience in HMR's previous, and far less successful mergers. Aventis has set clear project priorities and created interlocking R&D functions in the US, France, and Germany, with platform technology resources-wherever they're located-directed to priority projects. The result, Douglas believes, is a system that focuses on optimizing the global portfolio, not the site portfolio. The company's challenge now, and perhaps its biggest opportunity, comes from being a truly multinational organization. Aventis has core drug discovery and development sites in the US, France, and Germany, and has chosen to distribute decision-making equally among them. That facilitates outreach to academia and biotechs, but it's not the most efficient way to organize and requires extra time and work for communication.
by Mark L. Ratner
Among the never-ending consolidations in the pharmaceutical industry, Aventis SA —formed a year ago through the merger of Hoechst...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.